Correlation analysis to assess surrogate endpoints for overall survival (OS) in triplenegative breast cancer (TNBC)

被引：0
|
作者：
Perez-Granado, Judith
Kalucha, Ankit
Gala, Kinisha
Bodriagova, Olga
Vidal, Laura
Larvol, Bruno
Gramling, Mark
Saini, Kamal S.
机构：
[1] Larvol Grp LLC, San Francisco, CA USA
[2] LabCorp Drug Dev, Princeton, NJ USA
[3] Labcorp Drug Dev, Burlington, NC USA
[4] Cambridge Univ Hosp NHS Trust, Addenbrookes Hosp, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13089
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
    Maeda, Hideki
    Takeda, Kentaro
    Urushihara, Hisashi
    Kurokawa, Tatsuo
    CANCER REPORTS, 2021, 4 (03)
  • [22] Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)
    Xie, W.
    Sweeney, C.
    Regan, M.
    Nakabayashi, M.
    Buyse, M.
    Clarke, N.
    Collette, L.
    Dignam, J.
    Fizazi, K.
    Habibian, M.
    Halabi, S.
    Kantoff, P.
    Parulekar, W.
    Sandler, H. M.
    Sartor, O.
    Soule, H.
    Sydes, M.
    Tombal, B.
    Williams, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] Evaluation of surrogate endpoints for overall survival in patients treated with immunotherapies
    Jaiswal, Ashvin R.
    Bartkowiak, Todd
    Ager, Casey R.
    Chin, Renee
    Chen, Chao-Hsien
    Budhani, Pratha
    Ai, Midan
    Reilley, Matthew J.
    Sebastian, Manu M.
    Hong, David S.
    Curran, Michael A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [24] Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer
    Elia, E. G.
    Staedler, N.
    Ciani, O.
    Taylor, R. S.
    Bujkiewicz, S.
    CANCER EPIDEMIOLOGY, 2020, 64
  • [25] DISEASE-FREE SURVIVAL (DFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADULTS WITH RESECTABLE ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER: A CORRELATION META-ANALYSIS
    Leung, L.
    Kurt, M.
    Singh, P.
    Kim, I
    Donnellan, G.
    Kanters, S.
    VALUE IN HEALTH, 2021, 24 : S1 - S1
  • [26] PROGRESSION-FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER
    Beauchemin, C.
    Cooper, D.
    Lapierre, M. E.
    Yelle, L.
    Lachaine, J.
    VALUE IN HEALTH, 2012, 15 (07) : A414 - A414
  • [27] PROGRESSION-FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER
    Beauchemin, C.
    Cooper, D.
    Lapierre, M.
    Yelle, L.
    Lachaine, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 119 - 120
  • [28] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    CANCER RESEARCH, 2018, 78 (13)
  • [29] Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP).
    Sweeney, Christopher
    Xie, Wanling
    Regan, Meredith M.
    Nakabayashi, Mari
    Buyse, Marc E.
    Clarke, Noel W.
    Collette, Laurence
    Dignam, James J.
    Fizazi, Karim
    Habibian, Muriel
    Halabi, Susan
    Kantoff, Philip W.
    Parulekar, Wendy R.
    Sandler, Howard M.
    Sartor, Oliver
    Soule, Howard R.
    Sydes, Matthew Robert
    Tombal, Bertrand F.
    Williams, Scott G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Surrogate endpoints for prostate cancer survival: A secondary analysis of RTOG 9202
    Ray, M. E.
    Bae, K.
    Hussain, M. H. A.
    Hanks, G. E.
    Shipley, W. U.
    Sandler, H. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S81 - S82
12345